Navigation Links
Upending a cancer dogma
Date:7/2/2014

Researchers at the University of California, San Diego School of Medicine say a protein essential to regulating cell cycle progression the process of cell division and replication activates a key tumor suppressor, rather than inactivating it as previously thought.

"The finding is the result of literally 20 years of work in my lab," said Steven F. Dowdy, PhD, professor in the Department of Cellular and Molecular Medicine at UC San Diego. "It completely turns upside-down what was thought to be a fundamental aspect of cell cycle progression in all cancer cells driven by one of the most common genetic pathways mutated in cancer, namely the p16-cyclin D pathway."

The findings are published in the journal eLife.

Cyclin D is synthesized during the first stage of cell replication and is believed to help drive the complex, multi-stage process, including interaction with the retinoblastoma (Rb) protein, whose function is to prevent excessive cell growth by inhibiting cell cycle progression until a cell is ready to divide. Rb acts as a tumor suppressor.

But mutated or dysfunctional Rb is associated with several major cancers and Cyclin D has long been described as an oncogene that promotes cancer because it was believed to inactivate the Rb tumor suppressor function through a process called phosphorylation, which involves phosphate molecules being added to proteins, essentially turning them on or off.

Dowdy and colleagues painstakingly counted the number of phosphates added to Rb during cell cycle progression. There are as many as 14, but the scientists found that cyclin D adds just a single phosphate at one, and only one, of the 14 locations during the early G1 phase of cell cycle progression, essentially make 14 different versions of the Rb tumor suppressor. The single phosphate serves to activate Rb, not inactivate it as had been thought for over 20 years.

The researchers said the findings fundamentally change the understanding of G1 cell cycle regulation and the molecular origins of many associated cancers. It is critically important to understand how a genetic pathway actually functions and the consequences of interrupting it, especially in this case where there are multiple drug inhibitors of cyclin D being tested in clinical trials for breast cancer.

Moreover, how the next cyclin, cyclin E, that actually does inactivate Rb becomes activated has not been heavily investigated because it was thought to be the less important second domino, whereas we now know it is the first domino, added Dowdy.


'/>"/>

Contact: Jackie Carr
jcarr@ucsd.edu
619-543-6163
University of California - San Diego
Source:Eurekalert  

Related medicine news :

1. Cancer Research UKs new funding scheme to nurture future world-leading scientists
2. Biomarker predicts effectiveness of brain cancer treatment
3. GW researcher receives more than $1 million in grants to study epigenetics of pancreatic cancer
4. For cancer patients, sugar-coated cells are deadly
5. Mayo Clinic: Proton therapy has advantages over IMRT for advanced head and neck cancers
6. Mayo Clinic researchers reveal treasure trove of genes key to kidney cancer
7. Enlightening cancer cells
8. Cancer risk: Aspirin and smoking affect aging of genes
9. EORTC presents European solution for effective cancer drug development
10. New approach identifies cancer mutations as targets of effective melanoma immunotherapy
11. Case Western Reserve, University Hospitals fundraising for adolescent, young adult cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Upending a cancer dogma
(Date:3/22/2017)... ... March 22, 2017 , ... The Rett Syndrome Research ... neurological disorder that afflicts 350,000 individuals worldwide. Rett Syndrome is caused by ... exclusively strikes females. Following a normal infancy, Rett Syndrome takes effect in ...
(Date:3/22/2017)... (PRWEB) , ... March 22, 2017 , ... ... Bragdon to its Department of Orthopedic Surgery, Division of Hand, Upper Extremity and ... orthopedic surgery. She is board-certified in both Orthopedics and Hand Surgery. ...
(Date:3/22/2017)... ... March 22, 2017 , ... ... lab with extensive therapeutic experience and operational excellence in oncology clinical trials, proudly ... trial for the treatment of non-small cell lung cancer and small cell lung ...
(Date:3/22/2017)... NY (PRWEB) , ... March 22, 2017 , ... The ... communities in the greater Nassau County region, is embarking on a combined charity effort ... cancer. , For the last 25 years, the Great Neck Breast Cancer Coalition ...
(Date:3/22/2017)... ... March 22, 2017 , ... Schneider Insurance and Financial, a southern ... throughout the Yellowstone Valley region, is launching a charity event aimed at raising local ... in all of Montana State, and is home to a broad variety of animals ...
Breaking Medicine News(10 mins):
(Date:3/22/2017)... PUNE, India , March 23, 2017 ... 2017 - 2021, a latest research report. The global ... market is shift of surgeons focus toward minimally invasive ... popular or limited to few developed countries having high ... ...
(Date:3/22/2017)... , 22 de marzo de 2017 /PRNewswire/ ... global lĂ­der de soluciones de productos y servicios ... hoy que ha adquirido EPL Archives, Inc., una ... los clientes en todo el ciclo de vida ... ofreciendo una muestra de archivo, almacenamiento de documentos ...
(Date:3/22/2017)... 22, 2017 Research and Markets has announced ... & Trends - Industry Forecast to 2025" report to their ... The ... CAGR of around 10.9% over the next decade to reach approximately ... the market estimates and forecasts for all the given segments on ...
Breaking Medicine Technology: